Global and United States Kidney Cancer Drug Market Size, Status and Forecast 2020-2026

1 Report Overview

• 1.1 Study Scope
• 1.2 Market Analysis by Type
  • 1.2.1 Global Kidney Cancer Drug Market Size Growth Rate by Type: 2020 VS 2026
  • 1.2.2 Nexavar (Sorafenib)
  • 1.2.3 Sutent (Sunitinib)
  • 1.2.4 Afinitor (Everolimus)
  • 1.2.5 Votrient (Pazopanib)
  • 1.2.6 Avastin (Bevacizumab)
  • 1.2.7 Inlyta (Axitinib)
  • 1.2.8 Torisel (Temsirolimus)
  • 1.2.9 Proleukin (Aldesleukin)
  • 1.2.10 Other
• 1.3 Market by Application
  • 1.3.1 Global Kidney Cancer Drug Market Share by Application: 2020 VS 2026
  • 1.3.2 Hospitals
  • 1.3.3 Clinics
  • 1.3.4 Research Center
  • 1.3.5 Other
• 1.4 Study Objectives
• 1.5 Years Considered

2 Global Growth Trends

• 2.1 Global Kidney Cancer Drug Market Perspective (2015-2026)
• 2.2 Global Kidney Cancer Drug Growth Trends by Regions
  • 2.2.1 Kidney Cancer Drug Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Kidney Cancer Drug Historic Market Share by Regions (2015-2020)
  • 2.2.3 Kidney Cancer Drug Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Market Restraints

3 Competition Landscape by Key Players

• 3.1 Global Top Kidney Cancer Drug Players by Market Size
  • 3.1.1 Global Top Kidney Cancer Drug Players by Revenue (2015-2020)
  • 3.1.2 Global Kidney Cancer Drug Revenue Market Share by Players (2015-2020)
• 3.2 Global Kidney Cancer Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.3 Players Covered: Ranking by Kidney Cancer Drug Revenue
• 3.4 Global Kidney Cancer Drug Market Concentration Ratio
  • 3.4.1 Global Kidney Cancer Drug Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Top 10 and Top 5 Companies by Kidney Cancer Drug Revenue in 2019
• 3.5 Key Players Kidney Cancer Drug Area Served
• 3.6 Key Players Kidney Cancer Drug Product Solution and Service
• 3.7 Date of Enter into Kidney Cancer Drug Market
• 3.8 Mergers & Acquisitions, Expansion Plans

4 Kidney Cancer Drug Breakdown Data by Type (2015-2026)

• 4.1 Global Kidney Cancer Drug Historic Market Size by Type (2015-2020)
• 4.2 Global Kidney Cancer Drug Forecasted Market Size by Type (2021-2026)

5 Kidney Cancer Drug Breakdown Data by Application (2015-2026)

• 5.1 Global Kidney Cancer Drug Historic Market Size by Application (2015-2020)
• 5.2 Global Kidney Cancer Drug Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Kidney Cancer Drug Market Size (2015-2026)
• 6.2 North America Kidney Cancer Drug Market Size by Type (2015-2020)
• 6.3 North America Kidney Cancer Drug Market Size by Application (2015-2020)
• 6.4 North America Kidney Cancer Drug Market Size by Country (2015-2020)
  • 6.4.1 United States
  • 6.4.2 Canada

7 Europe

• 7.1 Europe Kidney Cancer Drug Market Size (2015-2026)
• 7.2 Europe Kidney Cancer Drug Market Size by Type (2015-2020)
• 7.3 Europe Kidney Cancer Drug Market Size by Application (2015-2020)
• 7.4 Europe Kidney Cancer Drug Market Size by Country (2015-2020)
  • 7.4.1 Germany
  • 7.4.2 France
  • 7.4.3 U.K.
  • 7.4.4 Italy
  • 7.4.5 Russia
  • 7.4.6 Nordic
  • 7.4.7 Rest of Europe

8 China

• 8.1 China Kidney Cancer Drug Market Size (2015-2026)
• 8.2 China Kidney Cancer Drug Market Size by Type (2015-2020)
• 8.3 China Kidney Cancer Drug Market Size by Application (2015-2020)
• 8.4 China Kidney Cancer Drug Market Size by Region (2015-2020)
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 South Korea
  • 8.4.4 Southeast Asia
  • 8.4.5 India
  • 8.4.6 Australia
  • 8.4.7 Rest of Asia-Pacific

9 Japan

• 9.1 Japan Kidney Cancer Drug Market Size (2015-2026)
• 9.2 Japan Kidney Cancer Drug Market Size by Type (2015-2020)
• 9.3 Japan Kidney Cancer Drug Market Size by Application (2015-2020)
• 9.4 Japan Kidney Cancer Drug Market Size by Country (2015-2020)
  • 9.4.1 Mexico
  • 9.4.2 Brazil

10 Southeast Asia

• 10.1 Southeast Asia Kidney Cancer Drug Market Size (2015-2026)
• 10.2 Southeast Asia Kidney Cancer Drug Market Size by Type (2015-2020)
• 10.3 Southeast Asia Kidney Cancer Drug Market Size by Application (2015-2020)
• 10.4 Southeast Asia Kidney Cancer Drug Market Size by Country (2015-2020)
  • 10.4.1 Turkey
  • 10.4.2 Saudi Arabia
  • 10.4.3 UAE
  • 10.4.4 Rest of Middle East & Africa

11 Key Players Profiles

• 11.1 Active Biotech
  • 11.1.1 Active Biotech Company Details
  • 11.1.2 Active Biotech Business Overview
  • 11.1.3 Active Biotech Kidney Cancer Drug Introduction
  • 11.1.4 Active Biotech Revenue in Kidney Cancer Drug Business (2015-2020))
  • 11.1.5 Active Biotech Recent Development
• 11.2 Amgen
  • 11.2.1 Amgen Company Details
  • 11.2.2 Amgen Business Overview
  • 11.2.3 Amgen Kidney Cancer Drug Introduction
  • 11.2.4 Amgen Revenue in Kidney Cancer Drug Business (2015-2020)
  • 11.2.5 Amgen Recent Development
• 11.3 Bayer AG
  • 11.3.1 Bayer AG Company Details
  • 11.3.2 Bayer AG Business Overview
  • 11.3.3 Bayer AG Kidney Cancer Drug Introduction
  • 11.3.4 Bayer AG Revenue in Kidney Cancer Drug Business (2015-2020)
  • 11.3.5 Bayer AG Recent Development
• 11.4 Cipla Limited
  • 11.4.1 Cipla Limited Company Details
  • 11.4.2 Cipla Limited Business Overview
  • 11.4.3 Cipla Limited Kidney Cancer Drug Introduction
  • 11.4.4 Cipla Limited Revenue in Kidney Cancer Drug Business (2015-2020)
  • 11.4.5 Cipla Limited Recent Development
• 11.5 F. Hoffmann-La Roche
  • 11.5.1 F. Hoffmann-La Roche Company Details
  • 11.5.2 F. Hoffmann-La Roche Business Overview
  • 11.5.3 F. Hoffmann-La Roche Kidney Cancer Drug Introduction
  • 11.5.4 F. Hoffmann-La Roche Revenue in Kidney Cancer Drug Business (2015-2020)
  • 11.5.5 F. Hoffmann-La Roche Recent Development
• 11.6 Genentech
  • 11.6.1 Genentech Company Details
  • 11.6.2 Genentech Business Overview
  • 11.6.3 Genentech Kidney Cancer Drug Introduction
  • 11.6.4 Genentech Revenue in Kidney Cancer Drug Business (2015-2020)
  • 11.6.5 Genentech Recent Development
• 11.7 Glaxosmithkline PLC
  • 11.7.1 Glaxosmithkline PLC Company Details
  • 11.7.2 Glaxosmithkline PLC Business Overview
  • 11.7.3 Glaxosmithkline PLC Kidney Cancer Drug Introduction
  • 11.7.4 Glaxosmithkline PLC Revenue in Kidney Cancer Drug Business (2015-2020)
  • 11.7.5 Glaxosmithkline PLC Recent Development
• 11.8 Novartis AG
  • 11.8.1 Novartis AG Company Details
  • 11.8.2 Novartis AG Business Overview
  • 11.8.3 Novartis AG Kidney Cancer Drug Introduction
  • 11.8.4 Novartis AG Revenue in Kidney Cancer Drug Business (2015-2020)
  • 11.8.5 Novartis AG Recent Development
• 11.9 Onyx Pharmaceuticals
  • 11.9.1 Onyx Pharmaceuticals Company Details
  • 11.9.2 Onyx Pharmaceuticals Business Overview
  • 11.9.3 Onyx Pharmaceuticals Kidney Cancer Drug Introduction
  • 11.9.4 Onyx Pharmaceuticals Revenue in Kidney Cancer Drug Business (2015-2020)
  • 11.9.5 Onyx Pharmaceuticals Recent Development
• 11.10 Pfizer
  • 11.10.1 Pfizer Company Details
  • 11.10.2 Pfizer Business Overview
  • 11.10.3 Pfizer Kidney Cancer Drug Introduction
  • 11.10.4 Pfizer Revenue in Kidney Cancer Drug Business (2015-2020)
  • 11.10.5 Pfizer Recent Development
• 11.11 Abbott Laboratories
  • 10.11.1 Abbott Laboratories Company Details
  • 10.11.2 Abbott Laboratories Business Overview
  • 10.11.3 Abbott Laboratories Kidney Cancer Drug Introduction
  • 10.11.4 Abbott Laboratories Revenue in Kidney Cancer Drug Business (2015-2020)
  • 10.11.5 Abbott Laboratories Recent Development
• 11.12 Aveo Pharmaceuticals
  • 10.12.1 Aveo Pharmaceuticals Company Details
  • 10.12.2 Aveo Pharmaceuticals Business Overview
  • 10.12.3 Aveo Pharmaceuticals Kidney Cancer Drug Introduction
  • 10.12.4 Aveo Pharmaceuticals Revenue in Kidney Cancer Drug Business (2015-2020)
  • 10.12.5 Aveo Pharmaceuticals Recent Development
• 11.13 Immatics Biotechnologies
  • 10.13.1 Immatics Biotechnologies Company Details
  • 10.13.2 Immatics Biotechnologies Business Overview
  • 10.13.3 Immatics Biotechnologies Kidney Cancer Drug Introduction
  • 10.13.4 Immatics Biotechnologies Revenue in Kidney Cancer Drug Business (2015-2020)
  • 10.13.5 Immatics Biotechnologies Recent Development
• 11.14 Prometheus Laboratories
  • 10.14.1 Prometheus Laboratories Company Details
  • 10.14.2 Prometheus Laboratories Business Overview
  • 10.14.3 Prometheus Laboratories Kidney Cancer Drug Introduction
  • 10.14.4 Prometheus Laboratories Revenue in Kidney Cancer Drug Business (2015-2020)
  • 10.14.5 Prometheus Laboratories Recent Development
• 11.15 Exelixis
  • 10.15.1 Exelixis Company Details
  • 10.15.2 Exelixis Business Overview
  • 10.15.3 Exelixis Kidney Cancer Drug Introduction
  • 10.15.4 Exelixis Revenue in Kidney Cancer Drug Business (2015-2020)
  • 10.15.5 Exelixis Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

• 13.1 Research Methodology
  • 13.1.1 Methodology/Research Approach
  • 13.1.2 Data Source
• 13.2 Disclaimer